Fetal protection against bovine viral diarrhoea type 1 virus infection after one administration of a live-attenuated vaccine

Vet J. 2012 May;192(2):242-5. doi: 10.1016/j.tvjl.2011.05.011.

Abstract

A modified-live vaccine has been shown previously to prevent fetal infection with bovine viral diarrhoea virus (BVDV)-2 and, to some extent BVDV-1, when used in association with an inactivated vaccine in a two-step vaccination protocol. In this challenge study, the modified-live vaccine used alone was able to protect 13 heifers between 49 and 96 days of gestation at challenge from leucopenia and virus replication and, for a 4-month period, to prevent fetal infection. The efficacy of the BVDV-1f 22146/Han81 challenge was demonstrated by virus isolation from the fetuses of all nine non-vaccinated, control heifers. However, the small number of heifers tested meant that the vaccination failure rate could be as high as 10% in the field.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bovine Virus Diarrhea-Mucosal Disease / prevention & control*
  • Bovine Virus Diarrhea-Mucosal Disease / transmission
  • Cattle
  • Diarrhea Virus 1, Bovine Viral / immunology*
  • Dose-Response Relationship, Drug
  • Female
  • Fetal Diseases / prevention & control
  • Fetal Diseases / veterinary*
  • Infectious Disease Transmission, Vertical / prevention & control
  • Infectious Disease Transmission, Vertical / veterinary*
  • Pregnancy
  • Vaccination / veterinary*
  • Vaccines, Attenuated / administration & dosage
  • Viral Vaccines / administration & dosage*

Substances

  • Vaccines, Attenuated
  • Viral Vaccines